Nucs AI, the leader in AI-based radiology solutions, announced the launch of TrackPSMA, a breakthrough tool that gives physicians a faster, quantitative way to evaluate treatment response in prostate cancer.
TrackPSMA delivers a comparative assessment, quantifying disease changes from screening and follow-up scans, vastly improving a process that is often unstructured, manual, visually evaluated and inconsistently applied. In addition, TrackPSMA enables lesion-by-lesion tracking for true longitudinal analysis, allowing clinicians to monitor changes in individual lesions over time. The result is a standardized and evidence-based assessment, available in seconds, that gives physicians the confidence and rigor to act sooner for data-driven decisions.
"Being able to track disease progression lesion by lesion represents a fundamental shift in how experts understand and manage cancer over time," said Farid Yagubbayli, CTO of Nucs AI and chief architect of the company's AI solutions. "For the first time, we can measure therapy response objectively and reproducibly across scans, sites, and timepoints. It turns what was once a subjective visual comparison into a standardized, data-driven process that helps physicians act faster and with greater confidence."
"TrackPSMA also represents a critical step forward in applying AI to RLT treatment planning," added Nijat Ahmadov, CEO of Nucs AI. "By providing automated, standardized, and highly accurate treatment response assessments from PSMA-PET/CT scans, we're able to help physicians and drug manufacturers better understand the patient specific and tumor specific scenarios where treatments were effective and where there may still be potential for different approaches."
With the launch of TrackPSMA, physicians can now examine efficiently and objectively whether or not a selected patient is experiencing benefit from radiopharmaceutical treatment. When combined with Nucs AI's DeepPSMA and SelectPSMAsolutions, physicians have already seen a significant reduction in manual analysis, and better patient stratification for RLT. By streamlining workflows and minimizing errors, Nucs AI not only eases radiologists' administrative burden but also improves accuracy, reduces burnout, and lowers healthcare costs.
The launch of TrackPSMA marks another milestone in Nucs AI's broader mission to redefine the role of AI in medical imaging. Building on collaborations with Johns Hopkins and other leading institutions, Nucs AI is rapidly advancing its portfolio to meet the rising global demand for AI-powered radiology solutions. Visit Nucs AI's booth at RSNA 2025 to explore how the company is redefining evidence-based response evaluation for next-generation radiopharmaceutical therapies.
